13F reference period
Q2 2026
Security Snapshot
Helus Pharma Inc. - Common Shares, No Par Value (HELP) Institutional Ownership
CUSIP: 23256X407
13F Institutional Holders and Ownership History from Q3 2024 to Q3 2026
Institutions Reporting
97
Shares (Excl. Options)
29.88M
Full value: 29,881,651 · shares · 30 Jun 2026Price
$6.61
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Shares, No Par Value
- Symbol
- HELP on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 29,881,651
- Total 13F value
- $197,557,440
- Portfolio coverage rank
- 0%
- Share change
- +5,768,894
- Value change
- +$43,217,928
- Number of holders
- 97
- Shares outstanding
- 76,274,034
- SEC-reported price per share
- $12.29
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- HELP - Helus Pharma Inc. - Common Shares, No Par Value is tracked under CUSIP 23256X407.
- 97 institutions reported positions in Q2 2026.
- 7 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 78 to 97 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$115.67M
Full value: $115,673,504 · USD · 31 Mar 2026.$197.56M
Full value: $197,557,440 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 97 institutions filings for Q2 2026.
Security key
23256X407
13F reference period
Q2 2026
13F holders
97
13D/G owners
7
CIK / CUSIP context first
Open Q2 2026 holders
HELP full holder history
Helus Pharma Inc. SEC filings
Helus Pharma Inc. company facts
Helus Pharma Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 23256X407:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
7
Security
HELP
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Point72 Asset Management, L.P. | 9.9% | +41% | $37,759,482 | +$28,298,275 | 6,410,778 | +299% | Point72 Asset Management, L.P. | 30 Sep 2025 |
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | $30,106,217 | 5,111,412 | Venrock Healthcare Capital Partners III, L.P. | 31 Oct 2025 | |||
| So Eric H. L. | 5.8% | $50,653,586 | 4,423,894 | So Eric H. L. | 01 Sep 2026 | |||
| Glavine Paul | 5.8% | $50,465,371 | 4,407,456 | Glavine Paul | 01 Sep 2026 | |||
| Adage Capital Management, L.P. | 5.3% | $21,807,728 | 3,289,250 | Adage Capital Management, L.P. | 30 Jun 2026 | |||
| Sirenia Capital Management LP | 4.8% | $20,085,585 | 3,029,500 | Sirenia Capital Management LP | 30 Jun 2026 | |||
| Deep Track Capital, LP | 4.7% | -22% | $18,486,334 | -$5,262,159 | 2,391,505 | -22% | Deep Track Capital, LP | 31 Dec 2025 |
As of 30 Jun 2026,
97
institutional investors reported holding
shares of
Helus Pharma Inc. - Common Shares, No Par Value (HELP).
This represents
39%
of the company’s total
outstanding shares.
29.88M
Full value: 29,881,651 · shares · 30 Jun 202676.27M
Full value: 76,274,034 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
36%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Venrock Adviser, LLC | 5% | 3,851,654 | 0% | 0.77% | $25,459,433 |
| ORBIMED ADVISORS LLC | 4.3% | 3,271,400 | -15% | 0.41% | $21,623,954 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 4% | 3,060,000 | +337% | 0.03% | $20,226,600 |
| MILLENNIUM MANAGEMENT LLC | 3.5% | 2,632,156 | +9% | 0.01% | $17,398,551 |
| Rosalind Advisors, Inc. | 2.6% | 1,956,814 | +28% | 4.9% | $12,934,541 |
| SPHERA FUNDS MANAGEMENT LTD. | 2.1% | 1,620,753 | +64% | 1.5% | $10,713,177 |
| ACORN CAPITAL ADVISORS, LLC | 2% | 1,540,266 | 0% | 2.8% | $10,181,159 |
| DCF Advisers, LLC | 1.9% | 1,434,988 | +107% | 2.5% | $9,485,271 |
| Sio Capital Management, LLC | 1.7% | 1,300,000 | 1.5% | $8,593,000 | |
| Nan Fung Group Holdings Ltd | 1.3% | 987,222 | +115% | 5% | $6,525,537 |
| Boxer Capital Management, LLC | 1% | 790,000 | +23% | 0.39% | $5,221,900 |
| Logos Global Management LP | 0.98% | 750,000 | 0.21% | $4,957,500 | |
| CITADEL ADVISORS LLC | 0.81% | 620,959 | -29% | 0% | $4,104,539 |
| DAFNA Capital Management LLC | 0.67% | 514,061 | +3.2% | 0.65% | $3,397,943 |
| Walleye Capital LLC | 0.66% | 502,554 | 0.02% | $3,321,882 | |
| MORGAN STANLEY | 0.61% | 461,886 | -55% | 0% | $3,053,067 |
| Knott David M Jr | 0.49% | 370,000 | +5.7% | 1.3% | $2,445,700 |
| BANK OF AMERICA CORP /DE/ | 0.44% | 337,435 | 0% | $2,230,445 | |
| AdvisorShares Investments LLC | 0.38% | 292,711 | +50% | 0.23% | $1,934,820 |
| JANE STREET GROUP, LLC | 0.37% | 280,903 | +164% | 0% | $1,856,769 |
| JPMORGAN CHASE & CO | 0.31% | 237,828 | +10498% | 0% | $1,636,257 |
| ROYCE & ASSOCIATES LP | 0.3% | 232,078 | +50% | 0.01% | $1,534,036 |
| UBS Group AG | 0.29% | 218,726 | -8.2% | 0% | $1,445,779 |
| SUPERSTRING CAPITAL MANAGEMENT LP | 0.27% | 204,424 | 0.85% | $1,351,243 | |
| DIADEMA PARTNERS LP | 0.26% | 200,000 | 0.5% | $1,322,000 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
9
Headline period
Q2 2026
Rows shown
1-9 of 9
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 572,891 | $7,040,745 | +$6,555,229 | $12.29 | 13 |
| 2026 Q2 | 29,881,651 | $197,557,440 | +$43,217,928 | $6.61 | 97 |
| 2026 Q1 | 24,099,450 | $115,673,504 | -$35,645,486 | $4.80 | 78 |
| 2025 Q4 | 30,085,784 | $246,553,227 | +$165,579,566 | $8.18 | 78 |
| 2025 Q3 | 9,225,298 | $54,313,985 | +$4,566,007 | $5.89 | 72 |
| 2025 Q2 | 8,294,991 | $69,584,064 | +$4,016,201 | $8.39 | 53 |
| 2025 Q1 | 7,827,681 | $49,597,585 | +$5,442,242 | $6.34 | 53 |
| 2024 Q4 | 6,916,277 | $61,021,460 | -$124,070 | $8.82 | 50 |
| 2024 Q3 | 6,189,949 | $55,027,660 | +$55,027,660 | $8.89 | 40 |